Articles related to GUIDELINES/RECOMMENDATIONS

All vaccines are expected to be quadrivalent. Included in the update are expanded approval for Flucelvax Quadrivalent, administration adjustments for Afluria Quadrivalent, and higher dose vaccines for those 65 years old and older.

These recommendations “attempt to provide practical guidance for clinicians and patients regarding the use of nonstatin therapies to further reduce ASCVD risk in situations not covered by the guideline until such time as the scientific evidence base expands.”

The USPSTF comes to the conclusion that statin use has at least a moderate net benefit for adults aged 40 to 75 who have no prior history of CVD, at least one CVD risk factor, and an estimated 10-year CVD event risk of 10% or greater. There is at least a marginal net benefit from using statins to prevent CVD events and all-cause mortality in adults aged 40 to 75 who have no prior history of CVD, at least one of these risk factors, and an estimated 10-year CVD event risk of 7.5% to less than 10%. Still, is the evidence enough?

This review with case example explores pericarditis and myocarditis and implications on limiting exercise. The authors summarize relevant guidelines and provide their own conclusion and guidance. They offer a helpful algorithm combining the ESC, ACC, and AHA guidelines and suggest an additional element around limiting heart rate during an acute inflammatory episode.

Rakesh Jain, MD, MPH, a member of the steering committee for the Psych Congress, and co-authors Huy-Binh Nguyen, PhD, and Mousam Parikh, both of AbbVie, respond to inquiries regarding their study, which discovered a discrepancy between treatment recommendations and the prescription habits of clinicians treating bipolar disorder. The study’s motivation, the most important findings, and suggestions for doctors treating bipolar disorder who want to follow the most recent treatment recommendations are covered in Part 1 of this Q&A.

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.